Abstract Esophageal cancer (EC) is one of the most aggressive gastrointestinal malignancies, possessing an insidious onset and a poor prognosis. Numerous transcription factors and inflammatory mediators have been reported to play a pivotal role in the initiation and progression of this cancer. However, the specifics of the signaling network responsible for said factors, especially which elements are the critical regulators, are still being elucidated. Glycogen synthesis kinases 3 (GSK3)b was originally regarded as a kinase regulating glucose metabolism. Accumulating evidence demonstrated that it also played an essential role in a variety of cellular processes including proliferation, differentiation, inflammation, motility, and survival by regulating various transcription factors such as c-Jun, AP-1, b-catenin, CREB, and NF-jB. Aberrant regulation of GSK3b has been shown to promote cell growth in some cancers, while suppressing it in others, and thus may play an important role in the development of EC. This review will discuss our current understanding of GSK3b signaling, and its control of the expression and activation of various transcription factors that mediate the inflammatory response. We will also explore some of the known mediators of EC progression, and based on current literature, elucidate the potential roles and implications of GSK3 in this disease.
Introduction
Esophageal cancer (EC) is regarded as one of the most aggressive malignant tumors of the gastrointestinal tract. Whereas the majority of cases occur in Asia, especially in some provinces of central China like Henan, recent studies have shown that the frequency of new cases of this neoplasm is projected to be at a 10 % annual increase in Western Europe and the USA (Blot et al. 1991; Crew and Neugut 2004) . As the eighth most common cancer worldwide and the sixth leading cause of cancer deaths, this malignant tumor is characterized by rapid development and generally poor prognosis (Coleman et al. 2003) . For the patients with inoperable cancer, the median survival is estimated between 13 and 29 months. Even when an esophagectomy is performed, the five-year survival of EC patients is only 10-20 % (Coleman et al. 2003) . The astonishing high mortality of EC could be due to the relatively late stage of diagnosis, the rapid progression of the tumor, and the lack of understanding of the underlying cellular mechanism of the disease (Vallbohmer and Lenz 2006) . Various environmental factors including poor oral hygiene, diet, viral infection, and chemical exposure (Eslick 2010; Scully and Bagan 2009) have been reported to be risk factors. Accumulating evidence suggests that the alternation of transcription factors (TFs) activity and expression of multiple inflammatory mediators play a pivotal role in neoplastic transformation and tumorigenesis of EC. In this regard, TFs led to the expression of various genes (either pro-or anti-tumorigenesis) that are implicated in each stage of cancer development, mainly through controlling cell cycle and apoptosis. The inflammatory mediators could exert their effects on tumorigenesis directly or by modifying the activity of TFs. To date, how these TFs and inflammatory mediators are regulated, and which are the molecular key players is still poorly understood. Therefore, identifying the key players regulating these factors and elucidating the underlying interactions of this network will be beneficial to design the optimal therapeutic strategy for EC patients. Our and other studies (Jope et al. 2007; Jope and Johnson 2004; Wang et al. 2008 Wang et al. , 2011a demonstrated that glycogen synthesis kinases 3 (GSK3) is involved in many physiological and pathological processes including proliferation, differentiation, motility, and survival through regulating the activity of TFs and production of inflammatory mediators, which suggested that GSK3 could be a potential molecular target in the development of EC.
What Is GSK3 and How Does It Work?
GSK3 was originally isolated from skeletal muscle and is a critical enzyme involved in glycogen metabolism (Embi et al. 1980; Woodgett and Cohen 1984) . Recent studies have identified GSK3 as a point of convergence for numerous cell-signaling pathways involved in a multitude of cellular physiological processes including development, cell cycle, differentiation, motility, microtubule function, apoptosis, adhesion, and inflammation (Doble and Woodgett 2003; Jope and Johnson 2004; Kockeritz et al. 2006; Wang et al. 2011c) (Fig. 1) . The incredible number of cellular processes controlled by GSK3, either directly or indirectly, has been shown to be due to its ability to posttranslationally modify TFs via its ability to phosphorylate consensus site-specific serine or threonine residues (Ali et al. 2001; Jope and Johnson 2004) (Fig. 1) . Due to the ability of GSK3 to impact numerous intracellular signaling pathways, it is not surprising that the disregulation of GSK3 has been shown to be involved in the initiation or progression of several cancers. GSK3b has been shown to promote the growth of some cancers, e.g. pancreatic cancer, myeloma cancer, and colorectal cancer, while suppressing growth in others, e.g. lung cancer, EC, and breast cancer (Garcea et al. 2007; Kang et al. 2008; Zhou et al. 2008 ).
There are two major GSK3 isoforms, GSK3a and b, that are encoded by distinct genes and endowed with different functions in mammalian cells (Woodgett 1990 ). In addition, an alternative splice variant of GSK3b, referred to as GSK3b2, has also been identified in the brains of mice, rats, and humans (Mukai et al. 2002) . GSK3 is a constitutively active serine/threonine kinase under basal cellular conditions and phosphorylation results in a decrease of its activity. Initial studies assessing the cell-signaling pathways activated by insulin identified that insulin receptor signaling resulted in the activation of the phosphoinositide 3 kinase (PI3K) pathway and the subsequent phosphoinactivation of GSK3a (serine 21) or GSK3b (serine 9) by Akt (Cross et al. 1994) . Other cellular stimuli including growth factors (Brady et al. 1998) , phorbol esters (Shaw and Cohen 1999) , amino acids (Peyrollier et al. 2000) , Toll-like receptors (TLRs) (Wang et al. 2008) , T cell receptor , CD28 , and interleukin (IL) receptors ) have also been shown to phospho-inactivate GSK3a (serine 21), GSK3b (serine 9), or both (Fig. 1) . Phosphorylation of GSK3 can be mediated by Akt (Martin et al. 2005) , P70S6K (Peyrollier et al. 2000) , P90RSK (Saito et al. Fig. 1 Regulation of GSK3 and its substrates specificity. Amino acids, growth factors, TLRs, T cell receptor (TCR), CD28, and cytokine receptors have been shown to mediate the phosphoinactivation of GSK3. Activation of PI3K results in the generation of PIP3 that allows for the recruitment of Akt via its pleckstrin homology domain. Full activation of Akt occurs when it is phosphorylated at threonine 308 by PDK1 and serine 473 by PDK2/mTORC2. Upon activation, Akt can phosphorylate GSK3b (Ser9) that results in its inactivation. PKC and PKA also can phosphoinactivate GSK3. Active GSK3 exhibits a 100-1,000-fold increase in substrate specificity for pre-primed substrates, as compared to nonprimed substrates. N-terminal phosphorylation of GSK3b (Ser9) acts as a pseudo-substrate for the phosphate-binding site (arginine 96) of GSK3b and competes with pre-primed, but not non-primed substrates 1994b), PKC isoforms (Fang et al. 2002 ), or PKA (Sheridan et al. 2002 (Fig. 1) .
It has been shown that the activity of GSK3b is regulated by its phosphorylation, localization, and interaction with regulatory proteins and multiple-protein complexes (Ali et al. 2001; Jope et al. 2007 ). GSK3b prefers to phosphorylate substrates that are pre-primed (pre-phosphorylated) on a serine or threonine located around a five amino acid consensus sequence corresponding to serine/threonine -X-X-X-serine/threonine-P. The first serine or threonine in this motif is the residue to be phosphorylated by GSK3b, X can be any amino acid, and the last serine-or threonine-P is the pre-primed (pre-phosphorylated) residue (Fiol et al. 1987) (Fig. 1) . The preferential phosphorylation of pre-primed (pre-phosphorylated) substrates by GSK3b has been shown to increase substrate phosphorylation efficiency by more than 100-1,000-fold, as compared to non-primed substrates (Thomas et al. 1999 ). This characteristic of GSK3b to prefer pre-primed (pre-phosphorylated) substrates also plays a role in its inactivation by serine phosphorylation. Studies by Frame et al. (2001) demonstrated that mutating arginine 96 to alanine abrogated the ability of GSK3b to phosphorylate preprimed (pre-phosphorylated) substrates. Interestingly, the arginine 96 mutant of GSK3b could still phosphorylate nonprimed substrates and this activity was not affected by Aktmediated serine 9 phosphorylation of GSK3b. These findings demonstrated that the N-terminal phosphorylation of GSK3b on serine 9 acted as a pseudo-substrate for the phosphate-binding site (arginine 96) of GSK3b and competed for the binding to arginine 96 with pre-phosphorylated substrates.
Potential Involvement of GSK3 in the Progression of EC via the Regulation of Inflammatory Mediators
It has been reported that GSK3b plays a central role in inflammation control by regulating the innate and adaptive immune responses (Wang et al. 2011c) . Since the pivotal role of inflammation in the development of cancer has been established, we will discuss the effect of inflammation in the development of EC and how GSK3b contributes to this process via regulating the activity and expression of inflammation mediators.
Esophageal Cancer and Inflammation
Inflammation is a fundamental physiological process and is regarded as a primary host response to maintain tissue homeostasis upon tissue stressors such as infection or tissue damage. The close relationship between inflammation and tumorigenesis has been reported repeatedly by experimental, clinical, and epidemiological studies Patel and Woodgett 2008) . As early as in nineteenth century, Dr. Virchow observed the infiltration of leukocytes into tumors (Balkwill and Mantovani 2001) , and since then, an extensive body of literature has elucidated the contribution of inflammation in the initiation, growth, and metastasis of tumors (Colotta et al. 2009 ). Chronic inflammation was reported to initiate cancer by generating genotoxic stress, promoting cancer by inducing cellular proliferation and accelerating cancer development by enhancing angiogenesis and tissue invasion (Grivennikov et al. 2010; Li et al. 2011) . Epidemiological studies have shown up to 25 % of human cancers were caused by inflammation, and inflammatory diseases in different organs can predispose one to the initiation and development of certain types of cancers (Hussain and Harris 2007) . The strong association between inflammation and carcinogenesis has been observed in the liver, lung, prostate, ovaries, and especially gastroenterological organs. For instance, patients with chronic hepatitis B or C have a high risk of developing hepatocellular carcinoma. Chronic Helicobacter pylori gastritis is the most frequent and important causative factor for gastric cancer (Bornschein et al. 2010; Ernst and Gold 2000) . Inflammatory bowel disease patients are predisposed to colon cancer (Itzkowitz and Yio 2004) . Reflux esophagitis and Barrett's metaplasia are considered important factors in the development of esophageal adenocarcinoma (Zhang et al. 2009 ).
Inflammation is involved in the promotion and development of esophageal cancers either by regulating the activity and expression of risk factors (TFs, inflammation mediators, etc.) or inducing epigenetic alternation such as methylation of target genes. Take cytokines as an example, the nature and magnitude of cytokine production have been demonstrated to promote EC development. Fitzgerald et al. (2002a, b) analyzed cytokine expression and infiltration of inflammatory cells in different stages of EC and suggested that inflammatory mediators play an essential role during the progression of reflux esophagitis to Barrett's esophagus. Studies by Moons et al. (2008) also demonstrated the influences of cytokine gene polymorphisms on the development of esophageal cancer. They reported that a genetic profile predisposing an individual to a strong pro-inflammatory host response is associated with EC. Due to the increasing evidence demonstrating that GSK3 orchestrates the regulation of inflammatory mediators and several other cell cycle regulators, we will discuss the potential influence of GSK3 in the development of EC via regulating inflammatory mediators, apoptosis, TFs, and cell cycle (Figs. 2, 3, 4) .
Regulation of GSK3 in Inflammatory Responses
As a substrate of the PI3K/Akt pathway, our lab has demonstrated that GSK3 plays a critical role in regulating the nature and magnitude of innate and adaptive immune response (Rehani et al. 2009; Wang et al. 2008 Wang et al. , 2011c . In this regard, inhibition of GSK3b was demonstrated to suppress innate immune responses by reducing the production of IL-1b, IL-6, tumor necrosis factor (TNF), and IL-12 while concurrently enhancing the production of IL-10, IL-1 receptor antagonist (IL-1Ra), interferon (IFN)-b, and IFN-b induced IL-10 in TLRs-stimulated cells (Rehani et al. 2009; Wang et al. 2008 Wang et al. , 2011a . Moreover, many studies have also demonstrated the functional role of GSK3 in the adaptive immune responses. Welsh et al. (1996) reported that the activity of GSK3 was affected in mitogenstimulated human T cells. The role of GSK3 in regulating antigen-specific CD8
? T cells was subsequently reported by Ohteki et al. (2000) and showed that antigen-specific stimulation of CD8
? T cells resulted in the inactivation of GSK3, which enhanced IL-2 production and increased cellular proliferation. Other studies demonstrated that GSK3 was an important effector molecule involved in the B7-CD28 co-stimulatory signaling pathway. CD28 co-stimulation of T cells was shown to increase PI3K activity and mediate the inactivation of GSK3 (Pages et al. 1994; Wood et al. 2006) . In addition, studies using the Leishmania major infection model have shown that GSK3 inhibition suppressed Th1 responses (Ohtani et al. 2008 ) on a systematic level. Taken together, these findings demonstrate that GSK3 plays a prominent role both in innate and adaptive immunity by regulating cytokine production and proliferation of T cells. Fig. 2 Active GSK3 promotes an inflammatory cytokine profile. Different stimuli mediate inactivation of GSK3, and subsequently, suppress the production of pro-inflammatory cytokine production by regulating the activity of various transcription factors. While it has repeatedly been shown that chronic inflammation promotes tumorigenesis, several of these pro-inflammatory cytokines, namely TNF-a, IL-12, and IL-1b, have been shown to inhibit tumor growth and disease progression. Thus, low GSK3 activity may prevent tumorigenesis by limiting inflammation, but once the disease has been established, modulating GSK3 activation may be useful in controlling disease progression Fig. 3 The influence of GSK3 on transcription factors known to regulate cancer progression. GSK3 has been shown to promote the activation of p53, a known tumor suppressor. In addition, both AP-1 and b-catenin have been shown to promote EC progression. However, both are inhibited upon GSK3 activation, which may inhibit disease progression. Reciprocally, GSK3 may actually promote EC by facilitating the activation of NF-jB and STAT3, two transcription factors implicated in EC development. Further studies are needed to elicit the role of GSK3b in regulating these transcription factors in the context of EC tumorigenesis and disease progression Fig. 4 GSK3b mediated the control of cell cycle progression. Cyclin D1, A, and B have been shown to be overexpressed in EC and contribute to disease progression. Expression of a constitutively active GSK3 has been shown to increase expression of cyclin D1 by preventing its degradation. While no direct evidence exists demonstrating that GSK3 regulates cyclin A or B, GSK3 has been shown to facilitate p53 and c-Myc activation, which have been shown to regulate cyclin A and B. In addition, GSK3 activation also leads to the downregulation of both p21 and p27, both potent EC suppressors. Collectively, this would indicate that GSK3 promotes the cell cycle conditions that facilitate EC progression; however, it is currently unclear if GSK3 actually is a key regulator of any of these cell cycle proteins in the context of EC Potential Influence of GSK3b on EC via Regulating Inflammatory Cytokine Production Cytokines generated by activated immune cells are considered important components in orchestrating the relationship between inflammation and cancer. Studies conducted over the last several years have elucidated the molecular mechanism of intracellular signaling pathways of inflammatory cytokines, for example IL-6, TNF, IL-12, and IFN-c for tumor development (Kundu and Surh 2008; Masuhara et al. 1997) . The involvement of cytokines in tumor development is mainly through activating a series of intracellular kinases, which subsequently leads to the activation of different TFs, such as nuclear factor (NF)-jB, signal transducer and activator of transcription (STAT3), and activator protein (AP)-1. The ability of GSK3b inhibition to differentially regulate the production of pro-and anti-inflammatory cytokine production and its functional role in adaptive immune responses suggests that it might play an important role in the progression of EC (Fig. 2 ). We will, therefore, discuss the potential influences of GSK3b in the development of EC through its ability to regulate inflammatory cytokine expression.
Il-12
IL-12 has been demonstrated to enhance the generation and activation of cytotoxic lymphocytes, and the production of cytokines, especially IFN-c in T lymphocytes and NK cells (Ma et al. 1996) . It has been shown that endogenous IL-12 is required not only for resistance to many pathogens but also for chemically induced tumors. Using experimental models, recombinant IL-12 was reported to have a dramatic anti-tumor effect on various tumors including esophageal cancer (Cardenes et al. 2010; Mu et al. 1995; Pham-Nguyen et al. 1999) . Moreover, genetic defects in IL-12 production have been shown to predispose individuals to EC (Cardenes et al. 2010) . IL-12 is believed to suppress tumor development by enhancing the production of IFN-c, activating a potent anti-angiogenic response, or by having a direct toxic effect on tumor cells (Kito et al. 2003; Voest et al. 1995) ; however, IL-12 levels in serum increase with the progression of tumor invasion (Diakowska et al. 2006) . In EC for example, the average level of IL-12 in the serum of esophageal cancer patients is significantly higher than that of healthy volunteers (Diakowska et al. 2006; Tsuboi et al. 2004 ). The survival rate of patients with EC who had high serum levels of IL-12 was significantly less than that of patients with low IL-12 levels (Tsuboi et al. 2004) . Van Standick et al. (2003) analyzed the serum levels of IL-12 and IFN-c in different stages of EC and found that the preoperative immune response was able to predict the development of major infections after esophageal cancer surgery. It is unclear if elevated IL-12 facilitates EC disease severity or if it is simply a symptom since IL-12 is known to have anti-tumor effects. The inverse association of IL-12 levels in tissue and serum in the development and prognosis of EC suggests a complex mechanism behind this process. Active GSK3b has been shown to enhance the production of IL-12 upon IFN-c stimulation. Thus, activation of GSK3b might suppress the progression of EC by enhancing the production of IL-12 (Fig. 2) .
Tumor Necrosis Factor
TNF treatment was reported to significantly reduce tumor response rates in immunodeficient mice, which suggested that the antitumor activity of TNF is, at least in part, mediated by the immune system (Eggermont et al. 2003) . TNF has been demonstrated to induce the production of other cytokines (e.g. IL-1, IL-8) and cytotoxic factors (e.g. nitric oxide (NO), reactive oxygen species) by macrophages, which can mediate tumor suppression in mice (Vujanovic 2001) . In contrast, TNF was also reported to possess tumor-promoting effects (Arnott et al. 2002) . It has been shown that low doses of TNF can promote the proliferation of some malignant cell lines (Ferrajoli et al. 2002) . Although the molecular details of such tumor-promoting activity are not clear, it is believed that TNF can affect the initiation or progression of cancer by a variety of mechanisms such as inducing DNA damage and inhibiting DNA repair by enhancing the production of genotoxic molecules (e.g. NO) in cancer cells or bystander cells (Dhar et al. 2002) ; enhancing expression of matrix metalloproteinases in malignant cells (Hanemaaijer et al. 1993) ; or driving the overexpression of various pro-cancer factors (e.g. E-selectin, IL-8, VEGF, b-FGF, ephrin-A, and ICAM-1) (Cheng and Chen 2001; De Cesaris et al. 1999; Yoshida et al. 1997 ). In the development of EC, TNF polymorphisms have been shown to be strongly associated with tumor development. For example, gene polymorphism of TNF is associated with an increased risk of EC development and might be a useful marker to predict the risk of EC (Menke et al. 2012) . Using various human EC cell lines, Saito et al. (1994a) reported the significant antitumor effects of recombinant human TNF. Moreover, increased TNF was reported to enhance the radiosensitivity of EC patients by interacting with ionizing radiation and subsequently produced greater tumor regression and a delay in tumor regrowth (Gupta et al. 2003) . In contrast to the anti-EC effects of TNF, there are also several reports that have shown that TNF can promote EC via enhancing expression of oncogenes like c-Myc and b-catenin (Tselepis et al. 2002) . These conflicting results about the function of TNF Arch. Immunol. Ther. Exp. (2014) 62:131-144 135 in EC suggest that further clinical investigation with a large number of patients or experiments using animal models should be performed to assess the therapeutic value of TNF. Most likely, the concentration and timing of TNF production during tumor development will drastically alter the properties of TNF as either pro-or anti-tumorigenesis.
Our lab and others have demonstrated that GSK3b activity enhances the production of TNF in different cell types (Agarwal et al. 2013; Martin et al. 2005) , which potentially makes GSK3-mediated regulation of TNF a factor in EC development (Fig. 2) .
Il-6
Accumulating evidence demonstrates that IL-6 is associated with the initiation and progression of various cancers including EC. IL-6 functions by binding the IL-6 receptor which activates a cytoplasmic tyrosine kinase bound to gp130 (Murakami et al. 1993) . This leads to the activation of multiple signaling pathways involving MAPKs, PI3Ks, and STATs (Hirano et al. 1997) . In light of the reported involvement of IL-6 and its downstream targets in the regulation of cell proliferation, survival, and metabolism, it is not surprising that IL-6 signaling has also been implicated in tumorigenesis (Hodge et al. 2005) . In esophageal cancer, it has been reported that both IL-6 and IL-6R are expressed in tumor tissue (Leu et al. 2003) . Moreover, tissue concentration of IL-6 was significantly higher in the tumor than in the normal epithelium (Oka et al. 1996a ). Furthermore, studies by Oka et al. (1996b) demonstrated that esophageal squamous carcinoma cells (ESCC) simultaneously produced both IL-6 and IL-6R, which indicated that there might be an autocrine loop of IL-6 and IL-6R involved in the progression of ESCC. Through the rapid phosphorylation of gp130 and STAT3, IL-6 has been shown to repress the apoptosis of ESCC (Leu et al. 2003) . In addition, IL-6 has been shown to enhance the expression of vascular endothelial growth factor (VEGF), which has been shown to be essential for the development, growth, and progression of various tumors (Huang et al. 2002) . Thus, IL-6 mediated angiogenesis could be another mechanism used to influence the progression of EC. Studies by Oka et al. (1996a) have shown that the serum levels of IL-6 are frequently elevated in patients with EC and are closely associated with a poor prognosis of survival.
Collectively, these studies have demonstrated the protumorigenesis effect of IL-6 and inhibition of GSK3b has been established as a strong IL-6 suppressor in different cell types (Grzesiak et al. 2005; Martin et al. 2005 ). GSK3 inhibition might be an important therapeutic approach, at least in terms of IL-6, to suppress the progression of EC by diminishing the levels of IL-6 either in tumor tissue or serum.
Il-17A
IL-17A is a cytokine produced primarily by activated T cells including Th17 cells, NKT cells and cd T cells (Harrington et al. 2005; Park et al. 2005; Yao et al. 1995) . IL-17 can inhibit tumor growth by increasing the generation and activity of cytotoxic T lymphocytes (Benchetrit et al. 2002) . Compared with wild-type controls, IL-17-deficient mice were reported to display increased numbers of lung metastases and rapid tumor growth of MC38 colon adenocarcinoma (Kryczek et al. 2009 ). In the setting of therapy-induced inflammation, IL-17A signaling was demonstrated to be required for the generation of IFN-csecreting, tumor antigen specific T cell immunity during chemotherapy ). The effectiveness of mounting this protective anti-tumor immunity depends on IL-17 production, mainly from cd T cells. In contrast with the above mentioned antitumor effects, IL-17A was also observed to promote the progression of various tumors. Several studies showed that IL-17A is able to induce a wide range of angiogenic mediators, including VEGF and IL-8 (Honorati et al. 2006; Kehlen et al. 1999 ). In addition, the ability of IL-17A to induce IL-6 is another possible way to promote tumor growth through the IL-6 mediated, antiapoptotic pathway ). In the blood and tumor tissue of EC patients, Th17 percentages and Th17-related cytokines including IL-23, IL-6, and IL-1b was significantly increased (Chen et al. 2012a) . Further studies have shown that there is a positive correlation between the levels of IL-17 producing cells and the densities of CD8 ? T cells, as well as the CD57
? T cells in the tumor tissue of esophageal cancer. Prognosis analysis has shown that high levels of IL-17 producing cells correlate with improved survival in ESCC patients. Since production of IL-17 is promoted by GSK3 activity in different cell types (Beurel et al. 2010; Wang et al. 2011a ), GSK3 could be involved in the prognosis and the progression of EC via its ability to enhance IL-17 production (Chen et al. 2012a; Lv et al. 2011) (Fig. 2) .
IL-1b
IL-1b has been shown to act as a double-edged sword in the development of tumors. In the context of immunogenic chemotherapy, IL-1b is essential for the adequate polarization of IFN-c-producing CD8
? T cells, production of IL-17, and the generation of anti-tumor cd T cells Mattarollo et al. 2011 ). In the absence of the IL-1 receptor 1 or in the presence of IL-1Ra, dying tumor cells fail to prime cancer specific IFN-c producing CD8
? T cells (Ghiringhelli et al. 2009 ). On the other hand, excessive IL-1b production has been implicated in chronic inflammatory diseases and malignancies (Dinarello 2011) . IL-1b has been reported to be increased in a variety of tumors including pancreas, colon rectum, skin, fibrosarcomas, and B16 melanoma (Arlt et al. 2002; Krelin et al. 2007; Maihofner et al. 2003; Voronov et al. 2003) , and contributes to tumor proliferation, metastasis, and resilience (Mukhopadhyay et al. 2006; Wolf et al. 2001) . For esophageal squamous cell carcinoma, IL-1b was significantly overexpressed at both the mRNA and protein levels in the tumor tissue in patients (Chen et al. 2012b; Deans et al. 2006 ). Blockage of IL-1b is able to attenuate tumor growth, invasion ability, and treatment resistance of ESCC (Chen et al. 2012b ). Moreover, IL-1b levels significantly correlated with higher clinical stages, lower response rates to concurrent chemoradiotherapy, and higher recurrence rates after curative treatment (Chen et al. 2012b ). These results indicated that IL-1b is a significant predictive and prognostic molecular marker of EC and may be a promising molecular target for therapeutic intervention. However, as pointed out with IL-12, it is still unclear if elevated IL-1 levels are contributing to EC disease severity or are merely a sign of disease progression since it has been demonstrated that IL-1 has potent anti-tumor effects. Our studies (Martin et al. 2005; Rehani et al. 2009 ) identified the ability of GSK3b activation to enhance production of IL1b and suppress its antagonist IL-1Ra level indicating that GSK3 activation suppresses tumor progression through its ability to enhance IL-1 production (Fig. 2) .
All these inflammatory cytokines can act to either promote tumor initiation or suppress tumor growth. These paradoxical phenomena might be explained by the types of cells making the cytokine, the stimuli that cell is receiving, and the time of production of these cytokines relative to tumor progression. The complex effect of cytokines on tumor growth and development suggests that more studies on the function and mechanisms of GSK3 will help unravel the effects of these cytokines and identify potent therapeutic targets to control various stages of cancer.
GSK3b-Mediated Control of Apoptosis and Its Implications in EC
Apoptosis is a genetically controlled and evolutionarily conserved form of cell death that is of importance for normal embryonic development and for the maintenance of tissue homeostasis. Aberrant apoptosis is a major cause of neoplastic disorders and is an integral part of EC pathogenesis (Sugimura et al. 2012; Wang et al. 1998) . Apoptosis is controlled either by extrinsic, receptor-mediated, or intrinsic, mitochondria-mediated, signaling pathways that are composed of a series of kinases (caspases) and cytosolic proteins like Bcl-2 proteins (Li et al. 1997; Ola et al. 2011) . Bcl-2 proteins are a family comprised of over 20 members and are regarded as some of the key regulators of apoptosis. Higher levels of Bcl-2 and lower levels of Bax are frequently reported in EC (Chatzopoulos et al. 2007; Kang et al. 2007; Sarbia et al. 1996 Sarbia et al. , 1997 . A recent report showed that slight changes in the activation of GSK3b could affect the expression of Bcl-2 (Suzuki et al. 2009 ). Therefore, it is no surprise that inhibition of GSK3 was reported to suppress the development of cancers. Ghosh and Altieri (2005) reported that GSK3 ablation resulted in P53-dependent apoptosis, which suppresses the growth of colorectal cancer in mice. Further studies demonstrated that inhibition of GSK3b suppressed the production of Bcl-2, which enhanced apoptosis in different cancerous cells (Ban et al. 2010; Ougolkov et al. 2007 ). Studies by Tan et al. (2005) demonstrated that pharmacological-mediated inhibition of GSK3b was shown to enhance apoptosis by increasing p53-dependent activation of Bax, leading to cytochrome c release, loss of mitochondrial membrane potential, and caspase-9 processing. These studies strongly indicate that inhibition of GSK3b might be an effective therapeutic agent against the development of EC via employing different mechanisms to augment apoptosis. On the other hand, phospho-inactivation of GSK3b has been shown to boost the production of Bcl-2 by enhancing the activity of CREB-ATF-1 in the context of t-Darpp-mediated PI3K-Akt activation (Belkhiri et al. 2008 ) (t-Darpp: truncated isoform of dopamine and cyclic-AMP-regualted phosphoprotein of Mr 32,000). Other studies confirm this phenomenon by providing quantitative evidence that phosphorylation of Akt and subsequent inactivation of its substrate GSK3b are capable of suppressing apoptosis in invasive prostate cancer (Paweletz et al. 2001) . All these lines of evidence unveiled the complexity of GSK3b influences on cell apoptosis and cancer progression.
GSK3b Affects Tumorigenesis of EC through Transcription Factor Modification
Alternation of activity and/or expression of TFs plays different roles in tumorigenesis at different stages by altering the transcriptional machinery that regulates mRNA synthesis. Based on published literature, GSK3b regulates the stability of various oncogenic TFs such as the AP-1, NF-jB, c-Myc, b-catenin, P53, and STATs (Fig. 3) . Most of these TFs have been reported as physiological targets of GSK3b that undergo proteasomal degradation upon phosphorylation. Thus, summarizing the function of these TFs in the development of EC and the regulatory influence of GSK3b would direct us toward understanding the potential of GSK3b as a molecular target of EC and other cancers. AP-1, a dimeric transcription factor that is comprised of c-Jun and c-Fos, was shown to highly express in EC and was closely associated with the development of EC (Hussain et al. 2009; Jimeno et al. 2006 ). c-Jun has been reported to play a critical role in carcinogenesis and cell apoptosis via emigrating from the cytoplasm to the nucleus (Taira et al. 2012; Wang et al. 2011d) . GSK3b is able to directly phosphorylate c-Jun at Thr 239 and then promote its degradation (Wei et al. 2005) , which highlights another possible role for GSK3 in EC progression.
Activation of NF-jB promotes transcription of a wide variety of genes, which are related to inflammation and tumor growth (Baud and Karin 2009) . Many studies have shown that NF-jB plays a crucial role in the pathogenesis of esophageal adenocarcinoma (Abdel-Latif et al. 2004; Konturek et al. 2004; O'Riordan et al. 2005) . NF-jB is highly activated in EC samples (Abdel-Latif et al. 2004; O'Riordan et al. 2005) . Moreover, the expression of NF-jB in EC samples also correlated with the stage of the disease (Abdel-Latif et al. 2009 ). The activation of NF-jB in both inflammation and the carcinogenesis of EC suggests that the NF-jB pathway may play a mechanistic role in the survival pathway of tumor cells. GSK3b has been shown to phosphorylate p65 at Ser468 and negatively regulate its activity by promoting its degradation (Buss et al. 2004 ). Recent reports suggest that active GSK3b physically interacts with IjBa in normal epithelial cells (Ma et al. 2009 ) and then blocks NF-jB-dependent transcription by preventing IjBa degradation (Sanchez et al. 2003) . In contrast, our recent studies have demonstrated that inactivation of GSK3 suppressed the transcription of NF-jBmediated inflammatory cytokine production by decreasing the amount of cAMP response element-binding protein (CREB)-binding protein available to NF-jB (Wang et al. 2011b) . Two other reports confirmed our results by showing that increased levels of b-catenin mediated by GSK3b inhibition can antagonize NF-jB activity (Deng et al. 2002) . These conflicting results concerning the influence of GSK3 on NF-jB activation may be the result of different cell types used in the experiments. These studies indicate that GSK3b might control the progression of EC by modifying the activation of NF-jB in different stages of tumorigenesis. Numerous studies reported that phospho-inactivation of GSK3b results in the degradation of c-Myc and b-catenin (Cadigan and Liu 2006; Yada et al. 2004) . b-Catenin is a critical component of adherent junction in stratified squamous epithelium of esophageal. In normal epithelium, b-catenin is phosphorylated by GSK3b and then is degraded via ubiquitin-dependent proteasomes. However, when unphosphorylated, b-catenin accumulates in the cytoplasm and moves into the nucleus, which could lead to transcriptional activation of several oncogenes and promote cancer (Niessen and Gottardi 2008) . Overexpression of b-catenin has been shown in the nucleus of EC cells, which indicates GSK3b inhibition could promote the development of EC via regulating degradation and localization of b-catenin (Veeramachaneni et al. 2004; Zhou et al. 2002) .
P53 plays an important role in the regulation of apoptosis and cell growth. Loss of P53 activity is associated with uncontrolled cell cycle progression and tumor formation (Halm et al. 2000) . As a known tumor suppressor, p53 gene polymorphisms and its expression have been closely associated with the development and severity of EC (Wang et al. 1998 (Wang et al. , 2003 . Several studies have reported that GSK3b promotes the activation of p53 either by physical association or phosphorylation and post-translational modification (Eom and Jope 2009; Watcharasit et al. 2003) , which suggest that active GSK3b might be able to repress tumorigenesis and the development of EC by enhancing the activity of p53.
Finally, STAT3 is a key transcription factor involved in the inflammatory response, as well as in cell proliferation, differentiation, and cell survival (Brierley and Fish 2005) . It has been reported that increased activity of STAT3, either by inflammatory cytokines or other extracellular stimuli, participated in the tumorigenesis of EC (Leu et al. 2003; Yan et al. 2008) . Further studies have shown that inhibition of STAT3 activity suppressed the development of EC by enhancing cell apoptosis and cell cycle arrest (Turkson 2004) . Recent studies by Dr. Jope showed that activation of STAT3 is highly dependent on GSK3 and inhibition of GSK reduced the tyrosine phosphorylation of STAT3 (Beurel and Jope 2008) . Moreover, they observed that regulation of GSK3 on the STATs is selective: only STAT3 and STAT5 are activated by GSK3, not STAT1 and STAT6 (Beurel and Jope 2008) . Another finding by Moh et al. (2008) reported that STAT3 was able to regulate GSK3b levels in response to insulin, which indicated a possible positive feedback loop between GSK3b and STAT3 activation. The selectivity of GSK3 in STAT phosphorylation indicates more studies on the underlying mechanisms are needed to understand the function of GSK3b and its role in the development of EC in regard to STAT regulation (Fig. 3) .
All of the above TFs or signaling molecules are involved in the development of esophageal cancer and are directly regulated by GSK3b, indicating the importance of GSK3b in EC biology and the potential it possesses as a molecular target in EC treatment. However, as indicated, GSK3 activity may either promote activation of pro-EC factors, such as NF-jB and STAT3, or promote activation of anti-EC factors, such as p53. The timing of GSK3 activation during tumorigenesis and EC stages may explain this contradictory role GSK3 appears to play in this disease.
However, due to the limited reports on the expression and activation of GSK3b in EC, more studies on GSK3b expression profiles in different stages and histotypes of EC will be very helpful in establishing the relationship between GSK3b and the development of EC.
GSK3b Affects Tumorigenesis of EC via Regulating Cell Cycle
Cell cycle is a series of events that takes place in a cell leading to its division and replication. Three key classes of regulatory molecules, cyclins, cyclin-dependent kinase (CDKs), and CDK inhibitors (CDKI) determine a cell's progress through cell cycle. Overexpression of cyclin D1 and cyclin E has been observed in esophageal cancer cell lines and tumor tissues (Jiang et al. 1992; Matsumoto et al. 1999; Wang et al. 1996) . Further studies have reported that upregulation of cyclin D1/E in EC is achieved by regulating TFs such as AP-1, NF-jB, and b-catenin, which leads to the accumulation of the cyclins in the nucleus of cell (Arber et al. 1999; Verde et al. 2007) (Fig. 4) .
Incremental evidence has shown that overexpressing a constitutively active form of GSK3b increased cyclin D1 expression, induced cell entry into the S phase, and facilitated the proliferation of cancer (Cao et al. 2006; Mai et al. 2009 ). Since GSK3 activation prevents the degradation of cyclin D1, it stands to reason that inhibition of GSK3 might be an effective way to diminish cyclin D1 levels and inhibit EC progression. In additional to cyclin D and cyclin E, cyclin A and B are also overexpressed in human esophageal cancer (Furihata et al. 1996; Murakami et al. 1999 ). Although there is no evidence demonstrating that GSK3 directly regulates expression of cyclin A and B, these cyclins are primarily regulated by c-Myc and P53, which potentially identifies them as downstream GSK3b targets.
As a known CDK inhibitor, P21 (WAF1/CIP1) competitively binds with CDKs. Decreased expression of P21 enhances cell cycle progression in the presence of DNA damage. The expression of P21 has been reported to be significantly decreased in various cancers (Maritz et al. 2011; Verbeke et al. 2010) . In esophageal cancer, Kuwahara et al. (1999) reported that there is a close association between P21 expression and the five-year survival rate of patients. The P21-positive group had a five-year survival rate of 50 % compared to the 13.4 % survival rate of the P21-negative group, which suggested that P21 is a good prognostic indicator for EC (Kuwahara et al. 1999) . Moreover, expression and polymorphisms of P21 are closely related with therapeutic outcomes (Bahl et al. 2000; Nakamura et al. 2004) . Overexpression of GSK3b has been shown to directly downregulate P21 expression by phosphorylation at Thr57, leading to proteasome-mediated degradation, whereas inhibition of GSK3 with lithium chloride interfered with P21 degradation and increased P21 protein levels about ten-fold in EC (Rossig et al. 2002) . This finding indicates that inhibition of GSK3 might be a potential therapeutic approach for EC in the context of P21 expression (Fig. 4) .
Another CDKI, P27, showed the same effect on the development of esophageal cancer as P21. Overexpression of P27 has been reported to inhibit the growth and multiplication of esophageal cancer cells and induce apoptosis (Tong et al. 2011; Wu et al. 2003) . Moreover, using murine models with P27 knockout, Dr. Ellis found that P27 knockout mice were more likely to develop esophageal cancer (Ellis et al. 2001) . The expression of P27 has been reportedly regulated by forkhead O family TFs, which is modulated by the PI3K/GSK3 pathway (Ho et al. 2012; Nakao et al. 2008) . A discovery by our laboratory showed the direct suppressive effect of GSK3b inhibition on P27kip1 expression (Fig. 4) . Collectively, these data indicate that GSK3 inhibition may also increase P27 expression and improve prognosis outcomes in EC. In addition, CHOP/GADD153 (C/EBP-homologous protein) is an established apoptotic protein and tumor suppressor involved in multiple tumor types but so far, has not been studied in esophageal cancer. It has been shown that inhibition of GSK3 effectively reduced the expression of CHOP and enhanced cell survival (Meares et al. 2011) (Fig. 4) . Thus, GSK3 inhibition may play different roles in the progression of EC in the context of different proteins. More studies on the expression profile of CHOP/GADD153 in all stages of EC and the regulatory effect of GSK3b on CHOP/GADD153 will be very helpful in understanding the development of EC.
GSK3b has dual functions in the progression of different types of cancer. Phospho-inactivation of GSK3b has been reported in most cancers but so far, not in EC samples. Our unpublished data have also shown that the expression of phosphorylated GSK3 is significantly higher in the tumor tissue of EC than normal tissue. However, other studies indicate that GSK3b is overexpressed in many human malignancies that may offset the observed phospho-inactivation (Ougolkov et al. 2006; Shakoori et al. 2005) . Future work should aim at determining the role of GSK3 in an in vivo setting, under the pressures of the host immune response, and during various stages of the disease since GSK3 activity, like many proteins, could shift drastically during disease progression. Thus, determining the expression profile of GSK3b in different histotypes of ECs and deciphering the underlying signaling events involved can clarify the function of GSK3b in the development of EC and also highlight potential therapeutic applications.
Conclusion
Exploring the cell biology of EC reveals a complicated molecular signaling network, including numerous TFs and various inflammatory mediators controlling the initiation and development of EC. Due to the limited knowledge on the underlying mechanisms of EC regulators and their relationship with GSK3, continued work on the signaling pathways involved in tumorigenesis will be beneficial in the diagnostic and therapeutic approaches to the disease. The regulatory effects of GSK3b on various TFs, inflammatory cytokines, apoptosis, and cell cycle, have strong implications in the development, treatment, and projected outcomes of esophageal cancer. 
